Keith Loria is a contributing writer to Medical Economics.
Refoxy Pharmaceuticals Secures $9.7 Million to Explore Innovative Treatment for IPF
January 4th 2025Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the transcription factor FOXO3, Refoxy hopes to harness a key regulator that impacts numerous biological processes.
Read More
Study Highlights Critical Need For Improved Understanding of Childhood Interstitial Lung Disease
December 10th 2024Diagnostic criteria for pulmonary fibrosis and other fibrotic diseases in children are lacking. That void hampers an understanding of how disease progresses in children and adolescents and what the outcomes are.
Read More
Data From Long COVID Study Could Shed Light on Pulmonary Fibrosis Causes and Treatment
November 4th 2024Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
Read More
New Study Points Out Doubling of Hospitalizations and Healthcare Costs for PH-ILD
August 5th 2024A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
Read More
Blood-Based Immune Signatures Identified to Personalize MS Treatment
July 11th 2024A new study out of Germany, published in Science Translational Medicine in June, looked at peripheral blood mononuclear cells and serum collected from two independent cohorts of patients with MS to identify three endophenotypes of the disease.
Read More
New Study Reveals How Non-Coding FOXF1 Gene Deletions Lead to Fatal Lung Disease in Newborns
June 24th 2024A new study looked to show how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions can lead to a rare, lethal, genetic lung disease which causes respiratory failure in many newborns and infants.
Read More